Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

DISEASE CHARACTERISTICS:

Histologically confirmed malignancy, including, but not limited to, any of the following:

Renal cell carcinoma
Melanoma
Kaposi's sarcoma
Breast, prostate, colorectal, or lung adenocarcinoma
Bone and soft tissue sarcomas
Lymphoma
Myeloma
Tumors of neuroendocrine and endothelial cell origin
Stage IV disease
Refractory disease, resistant to established treatments, or no effective treatment available
Measurable or evaluable disease
CNS metastases allowed if no prior definitive therapy within the past 3 months and no glucocorticoids required

PATIENT CHARACTERISTICS:

ECOG performance status 0-1
Granulocyte count > 1,500/mm^3
Platelet count > 100,000/mm^3
Creatinine < 1.0 times upper limit of normal (ULN)
Creatinine clearance ≥ 60 mL/min
Bilirubin < 1.5 times ULN
AST/ALT < 1.5 times ULN
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 months after completion of study treatment

No history of any of the following:

Atrial fibrillation, atrial flutter, or other serious arrhythmia (excluding asymptomatic atrial and ventricular premature complexes)
Congestive heart failure currently requiring treatment
Angina pectoris
Other severe cardiovascular disease (i.e., New York Heart Association class III or IV heart disease)
No baseline ECG abnormalities suggestive of cardiac conduction delay, i.e., 1° or greater atrio-ventricular block and/or complete or incomplete (QRS > 120 ms) bundle branch block, or repolarization abnormalities (i.e., QTc ≥ 0.48 sec)
No systemic infections requiring antibiotics within the past 14 days
No known hepatitis B surface antigen positivity
Psychologically prepared to participate in study treatment

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
At least 4 weeks since prior interferon (IFN) therapy and/or ≤ 400 million units of IFN
At least 3 weeks since prior major surgery
At least 3 weeks since prior radiation therapy or chemotherapy
No prior solid organ allografts or allogeneic bone marrow transplantation
No concurrent daily glucocorticoids except for physiological replacement
No other concurrent medications known to prolong QT interval